Market Cap 281.85M
Revenue (ttm) 134.48M
Net Income (ttm) -38.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -28.96%
Debt to Equity Ratio 0.00
Volume 532,400
Avg Vol 914,128
Day's Range N/A - N/A
Shares Out 41.27M
Stochastic %K 83%
Beta 1.22
Analysts Hold
Price Target $10.06

Company Profile

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 521 7830
Website: rxsight.com
Address:
100 Columbia, Aliso Viejo, United States
focafoca99
focafoca99 Apr. 8 at 10:21 PM
$RXST highlighted the milestone of 300,000 Light Adjustable Lens implants and a heavy scientific presence at ASCRS 2026.
0 · Reply
OPmoney
OPmoney Apr. 6 at 7:21 PM
$RXST PSA #1 from 2025: As far as posting up insight on another patient's own LAL experience Nov. 2023 in one eye. There is some improvement. Can see because cataract was removed, however doctor's recent reco, after a year of own blood Serum-eyedrops for severe dry eye is now try Oxervate $100K eye drops. As of 10-days ago cornea looks like "sand paper." Same thing was said after lock-in over a year ago. NO FUN, plus this patient also suffers from Trigeminal neuralgia - no pain- only numbness on same side of face as LAL since. While there is visual improvement since the cataract was removed, the road post "lock-in" has been complicated by chronic ocular surface issues: The "Sandpaper" Effect: A recent exam revealed the cornea still looks like "sandpaper." This is the same condition reported after the initial lock-in over a year ago. The battle with corneal health continues. It’s a reminder that even with the best lens technology, the "window" (the cornea) has to be clear for it to work.
1 · Reply
OPmoney
OPmoney Apr. 6 at 7:09 PM
$RXST PSA: After undergoing a vitrectomy in both eyes this past September, then earning early onset cataracts - I just spent 10K and am now the proud owner of RxSight Light Adjustable Lenses (LALs) in each eye. Here is the current status: Distance Vision: Five days post-op and things are looking pretty clear in both. AMAZING how clear and bright everything is. The Rx does not match. There is a glare line in dark, looking at lightbulb from 11 to 5 in left and 10 to 4 in right. Near Vision: Currently using +2.75 readers for typing and close work. Maintenance: On a regimen of eye drops 3x daily. UV Dark Glasses mandatory outdoors, not so much indoors. Next Steps: Follow-up appointment scheduled in 10 days. So far, so good! It’s quite an investment, but the progress is encouraging. Added one new "floater" in left eye and two in the right. 1st lock-in is weeks away. Feel free to DM with any questions or concerns.
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:29 PM
$RXST to appear at the Needham Virtual Healthcare Conference on April 16.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 27 at 3:52 PM
$RXST Share Price: $6.33 Contract Selected: Sep 18, 2026 $5 Calls Buy Zone: $2.52 – $3.12 Target Zone: $4.34 – $5.30 Potential Upside: 62% ROI Time to Expiration: 174 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
KOWALSK1
KOWALSK1 Mar. 23 at 10:46 AM
$RXST Rxsight inc. ✅️ BUY ZONE 6.41 to 6.35 ✋️ RISK BELOW 6.18 💲PT. 6.75 6.80 7.20 7.64 8.10 + Follow for more
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 11 at 9:06 PM
$RXST RSI: 33.11, MACD: -0.3978 Vol: 0.51, MA20: 8.06, MA50: 8.87 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
erevnon
erevnon Mar. 9 at 4:03 PM
Stifel maintains RxSight $RXST at Hold and lowers the price target from $10 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 27 at 7:06 PM
$RXST RSI: 34.70, MACD: -0.3582 Vol: 0.45, MA20: 8.31, MA50: 9.55 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
erevnon
erevnon Feb. 26 at 5:43 PM
Wells Fargo maintains RxSight $RXST at Equal-Weight and lowers the price target from $13 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Latest News on RXST
RxSight, Inc. Announces Chief Financial Officer Transition

Dec 22, 2025, 5:15 PM EST - 4 months ago

RxSight, Inc. Announces Chief Financial Officer Transition


RxSight, Inc. Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 5 months ago

RxSight, Inc. Reports Third Quarter 2025 Financial Results


RxSight, Inc. Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 8 months ago

RxSight, Inc. Reports Second Quarter 2025 Financial Results


focafoca99
focafoca99 Apr. 8 at 10:21 PM
$RXST highlighted the milestone of 300,000 Light Adjustable Lens implants and a heavy scientific presence at ASCRS 2026.
0 · Reply
OPmoney
OPmoney Apr. 6 at 7:21 PM
$RXST PSA #1 from 2025: As far as posting up insight on another patient's own LAL experience Nov. 2023 in one eye. There is some improvement. Can see because cataract was removed, however doctor's recent reco, after a year of own blood Serum-eyedrops for severe dry eye is now try Oxervate $100K eye drops. As of 10-days ago cornea looks like "sand paper." Same thing was said after lock-in over a year ago. NO FUN, plus this patient also suffers from Trigeminal neuralgia - no pain- only numbness on same side of face as LAL since. While there is visual improvement since the cataract was removed, the road post "lock-in" has been complicated by chronic ocular surface issues: The "Sandpaper" Effect: A recent exam revealed the cornea still looks like "sandpaper." This is the same condition reported after the initial lock-in over a year ago. The battle with corneal health continues. It’s a reminder that even with the best lens technology, the "window" (the cornea) has to be clear for it to work.
1 · Reply
OPmoney
OPmoney Apr. 6 at 7:09 PM
$RXST PSA: After undergoing a vitrectomy in both eyes this past September, then earning early onset cataracts - I just spent 10K and am now the proud owner of RxSight Light Adjustable Lenses (LALs) in each eye. Here is the current status: Distance Vision: Five days post-op and things are looking pretty clear in both. AMAZING how clear and bright everything is. The Rx does not match. There is a glare line in dark, looking at lightbulb from 11 to 5 in left and 10 to 4 in right. Near Vision: Currently using +2.75 readers for typing and close work. Maintenance: On a regimen of eye drops 3x daily. UV Dark Glasses mandatory outdoors, not so much indoors. Next Steps: Follow-up appointment scheduled in 10 days. So far, so good! It’s quite an investment, but the progress is encouraging. Added one new "floater" in left eye and two in the right. 1st lock-in is weeks away. Feel free to DM with any questions or concerns.
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:29 PM
$RXST to appear at the Needham Virtual Healthcare Conference on April 16.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 27 at 3:52 PM
$RXST Share Price: $6.33 Contract Selected: Sep 18, 2026 $5 Calls Buy Zone: $2.52 – $3.12 Target Zone: $4.34 – $5.30 Potential Upside: 62% ROI Time to Expiration: 174 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
KOWALSK1
KOWALSK1 Mar. 23 at 10:46 AM
$RXST Rxsight inc. ✅️ BUY ZONE 6.41 to 6.35 ✋️ RISK BELOW 6.18 💲PT. 6.75 6.80 7.20 7.64 8.10 + Follow for more
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 11 at 9:06 PM
$RXST RSI: 33.11, MACD: -0.3978 Vol: 0.51, MA20: 8.06, MA50: 8.87 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
erevnon
erevnon Mar. 9 at 4:03 PM
Stifel maintains RxSight $RXST at Hold and lowers the price target from $10 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 27 at 7:06 PM
$RXST RSI: 34.70, MACD: -0.3582 Vol: 0.45, MA20: 8.31, MA50: 9.55 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
erevnon
erevnon Feb. 26 at 5:43 PM
Wells Fargo maintains RxSight $RXST at Equal-Weight and lowers the price target from $13 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
DrLukas19
DrLukas19 Feb. 26 at 4:38 PM
$RXST not a good look. Seems the LAL effictivness vs. fixed IOL is not as large as once previously thought. The tech seems promising but the physician adoption and utilization rate is telling a different story.
0 · Reply
healthcareguru
healthcareguru Feb. 26 at 3:15 PM
$RXST Time to Buy…turnaround story in play with adult mgmt in place. That was the last cut, reset to estimates…now it’s a beat/raise story with material multiple expansion potential. Realistic to see $15-20 in a year. 👍 $IHI $XLV $IWM $XBI
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 25 at 9:13 PM
$RXST Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.22 down -46.67% YoY • Reported revenue of $32.61M down -18.92% YoY • RxSight provided full year 2026 guidance, projecting revenue of $120.0 to $135M, gross margin of 70% to 72%, and operating expenses between $150M and $160M, reflecting lower LDD placements.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 21 at 10:48 PM
$RXST Current Stock Price: $8.63 Contracts to trade: $7.5 RXST Mar 20 2026 Call Entry: $2.40 Exit: $3.07 ROI: 28% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
topstockalerts
topstockalerts Feb. 17 at 1:08 PM
$RXST there it goes!! 🚨
0 · Reply
char13
char13 Feb. 17 at 12:27 PM
$PLYX 100% $BODI 12% $CMPS 16% $RXST 25% $OBAI 92%
0 · Reply
char13
char13 Feb. 17 at 10:50 AM
$RXST value play
0 · Reply
char13
char13 Feb. 17 at 10:48 AM
$RXST cataract surgery tool with a bunch of revenue. Looks like a winner here
0 · Reply
Ericvule
Ericvule Feb. 13 at 4:24 PM
$RXST still here…let’s get it
0 · Reply
Horseheels
Horseheels Feb. 11 at 2:59 PM
0 · Reply
erevnon
erevnon Jan. 20 at 2:50 PM
Piper Sandler maintains RxSight $RXST at Neutral and raises the price target from $10 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply